... considered significant at p < 0.05. Statistical analyses were performed using SAS software version 9.4. Tables and figures were produced with GraphPad Prism version 7. Small for gestational age Growth hormone Gonadotropin-releasing hormone analog Intrauterine growth retardation Final height...

... and in isolated GH deficiency, this does not generally seem to be the case in hypergonadotrophic hypogonadism due to Turner syndrome (TS) and this is (anecdotally) the usual hormonal profile in NS children and adults. Precocious or ‘exaggerated’ adrenarche can be associated with intrauterine growth retardation...

...Assunta Albanese; Richard Stanhope Since the early 1970s, it has been demonstrated that growth hormone (GH) treatment improves the short-term growth rate of children with short stature due to intrauterine growth retardation (IUGR). However, it is only in recent years that studies have been...

...Michael A. Preece There is a remarkable scarcity of data concerning puberty in children born with intrauterine growth retardation (IUGR). What little there is suggests that puberty occurs at a normal age compared with the general population, but a little early compared with other short children...

.... Experimentally, the maternal administration of GH and IGF-I can affect placental function and thus influence fetal growth; this may suggest therapeutic approaches to the treatment of intrauterine growth retardation (IUGR) in utero. Both experimental and clinical evidence support our hypothesis that IUGR...

...A. Albanese; R. Stanhope The anthropometric response to 7 years of GH treatment was assessed in 11 short children with Russell-Silver syndrome (RSS) and in 5 with non-dysmorphic intrauterine growth retardation (NRSS). GH treatment induced a significant increase (p < 0.0001) in the mean height...

...Ilse E.A. van der Reijden-Lakeman; Froukje M.E. Slijper; Jeanette E.W.M. van Dongen-Melman; Wouter J. de Waai; Frank C. Verhulst The objective of this study was to assess self-concept in children with short stature after intrauterine growth retardation (IUGR), before and after 2 years of growth...

... with placental development, and by the specific alterations of EGF receptors in intrauterine growth retardation. In addition, human placenta specifically secretes placental growth hormone, the level of which is significantly decreased in the sera of pregnant women bearing a fetus with intrauterine growth...

...A. Albanese; R. Stanhope Twenty-five short children (6F, 19M) with intrauterine growth retardation were treated with daily subcutaneous injections of biosynthetic human growth hormone for 4 years. The treatment was commenced at a chronological age of 6.3 years (range 2.1-9.8). Eighteen...

... children whose growth failure had a postnatal onset, and not significantly correlated with the response to conventional tests. 26 of the 52 intrauterine growth retardation (IUGR) patients were re-tested with GHRH in similar conditions after 6-12 months of daily subcutaneous injections of GH and 2 days...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Intrauterine growth retardation Growth hormone treatment Perception of stature Growth expectations Psychosocial...

...Raquel Coelho; Jonathan Wells; John Symth; Robert Semple; Stephen O'Rahilly; Simon Eaton; Khalid Hussain Background: Hypoglycaemia is common in preterm and intrauterine growth retarded (IUGR) newborns. Although preterm and IUGR infants have limited adipose tissue stores, the role of adipose tissue...

..., neurophil density and thickness, and myelination. Recently, magnetic resonance imaging data have shown reduced cortical volume in brains of those born small [ 32 ]. This suggests that, although we have traditionally considered head sparing to be a feature of intrauterine growth retardation, it is only...

...M.M. van Weissenbruch; H.A. Delemarre-van de Waal Fetal growth retardation appears to be associated with an increased risk of premature adrenarche, early puberty, polycystic ovary syndrome and associated fertility problems. In a rat model of intrauterine growth retardation, based on ligation...

... factors, particularly body mass index (BMI) at the time of observation. Adipose tissue Catch-up growth Insulin resistance Intrauterine growth retardation Type 2 diabetes Our own prospective case-control study includes more than 1,500 individuals who, at the time of observation, were 22...

... α present in intrauterine growth retardation (IUGR) and induce insulin resistance. It has been proposed that the reduced insulin sensitivity may result from adaptation to an adverse in utero environment during a critical period of development. We have investigated postnatal insulin resistance in 60...

... into an integrated conceptual framework on the sources and mediators of neurocognitive and psychosocial outcomes in intrauterine growth retardation and SGA. This framework depicts two distinct therapeutic pathways by which GH therapy may improve neurocognitive and behavioural outcomes. The first (‘traditional...

... at age 1 year, which was indicative of insulin resistance, even though they were still lighter than appropriate for age birthweight controls [ 49 ]. Small for gestational age Growth hormone Intrauterine growth retardation Insulin resistance Babies born small for gestational age (SGA...

... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Intrauterine growth retardation Growth...

.... The function and handling of the PenMate TM were evaluated in a Dutch trial by 27 GH-treated children with intrauterine growth retardation, aged 4–16 years, and their parents. All children were accustomed to using the Nordiject ® pen. The evaluation of the PenMate TM was based on a questionnaire. A similar...